Who makes Dexycu, 9% Intraocular Suspension?

Dexycu, 9% Intraocular Suspension is developed by Silverstein Eye Centers.

What development phase is Dexycu, 9% Intraocular Suspension in?

Dexycu, 9% Intraocular Suspension is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Dexycu, 9% Intraocular Suspension

Silverstein Eye Centers · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Dexycu, 9% Intraocular Suspension
Sponsor	Silverstein Eye Centers
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Intraoperative Dexamethasone on Post-op Dry Eye (PHASE4)
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery (PHASE4)
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dexycu, 9% Intraocular Suspension CI brief — competitive landscape report
Dexycu, 9% Intraocular Suspension updates RSS · CI watch RSS
Silverstein Eye Centers portfolio CI